Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II SubstudyDepartment of Cardiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Zealand University Hospital, Roskilde, Denmark .
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark .
University of California, San Diego, CA, USA.
Cardiovascular Research Foundation, New York, NY, USA.
Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden. (J.P.).
St. Olav's Hospital, Trondheim, Norway .
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway (A.I.L.).
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden; Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund University, Lund, Sweden; The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Science for Life Laboratory, Gothenburg University, Gothenburg, Sweden.
Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden; School of Health and Welfare, Dalarna University, Falun, Sweden; Center for Clinical Research Dalarna, Falun, Sweden.
The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden .
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Division of Cardiovascular Medicine, Vascular Medicine Program, Sulpizio Cardiovascular Center, University of California, San Diego, CA, USA.
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
St. Francis Hospital, Roslyn, NY .
Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden; University of California, San Diego, CA, USA.
Show others and affiliations
2026 (English)In: Arteriosclerosis, Thrombosis and Vascular Biology, ISSN 1079-5642, E-ISSN 1524-4636, Vol. 46, no 8, article id e324430Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Lipidomics, the comprehensive profiling of circulating lipid species, has emerged as a powerful tool to investigate metabolic alterations underlying coronary atherosclerosis. Understanding the mechanisms driving high-risk vulnerable plaque formation and progression to myocardial infarction remains a key therapeutic priority. This study investigates associations between circulating lipid metabolites and imaging-defined features of vulnerable coronary plaque.
METHODS: Following revascularization, patients with myocardial infarction underwent 3-vessel coronary artery imaging with near-infrared spectroscopy and intravascular ultrasound to assess nonflow-limiting plaques for lipid core burden index and plaque burden. Multivariable models evaluated associations between 424 lipid metabolites in plasma, quantified by mass spectrometry, pan-coronary lipid, pan-coronary plaque burden, and high-risk vulnerable plaque measures (maximum lipid core burden index within any 4-mm segment across the entire lesion ≥324.7 and plaque burden ≥70%) in 877 patients. Findings were validated in the SCAPIS study (Swedish Cardiopulmonary Bioimage Study) using coronary computed tomography angiography-based measures of coronary artery calcium score and segment involvement score.
RESULTS: We identified 156 significant associations (P<0.05) between lipid metabolites and coronary plaque characteristics across 39 metabolic pathways. Sphingomyelins were inversely associated with all plaque metrics, and 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), a phosphatidylethanolamine, was positively associated with all plaque metrics. After correcting for multiple testing, 27 lipid species across 7 pathways remained significant (q<0.05). The majority were linked to pan-coronary lipid burden, with the strongest inverse association observed for sphingomyelin d18:1/22:1, d18:2/22:0, and d16:1/24:1. Similar inverse patterns were seen for select dihydrosphingomyelins and fatty acid dicarboxylates. In contrast, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) remained positively associated with pan-coronary lipid. In the SCAPIS validation cohort, 19 of the 27 significant lipid associations were successfully replicated (q<0.05).
CONCLUSIONS: This study is the first to demonstrate that sphingomyelins are negatively and 1-palmitoyl-2-oleoyl-GPE (16:0/18:1) positively associated with vulnerable coronary plaque features based on multimodality intracoronary imaging in patients with myocardial infarction. Moreover, these associations were validated in a large cohort using coronary computed tomography angiography-derived measures of plaque burden. These novel results may enable the development of new diagnostic and therapeutic strategies.
Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2026. Vol. 46, no 8, article id e324430
Keywords [en]
atherosclerosis, lipidomics, myocardial infarction, sphingomyelins, ultrasonography, interventional
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-129673DOI: 10.1161/ATVBAHA.125.324430PubMedID: 42345096OAI: oai:DiVA.org:oru-129673DiVA, id: diva2:2082875
2026-07-012026-07-012026-08-11Bibliographically approved